Top Markets
#1 Black Phoenix Black Phoenix +342.75%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +61.75%
#4 Gold Park Gold Park +55.03%
#5 Acurast Acurast +36.76%
#6 BasedHype BasedHype +29.66%
#7 Cryptopia Cryptopia +22.04%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.03%
#9 Avantis Avantis +18.81%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +14.74%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Destiny Pharma plc Destiny Pharma plc

Destiny Pharma plc

DEST
Rank in Stocks #41142
Destiny Pharma plc is a biotechnology company based in Brighton, UK, founded in... Destiny Pharma plc is a biotechnology company based in Brighton, UK, founded in 1996, specializing in the identification, progression, and market introduction of pharmaceutical solutions for infectious diseases. The company's clinical pipeline includes NTCD-M3, currently in Phase III trials to prevent recurring Clostridioides difficile infections. Its XF-73 program features XF-73 Nasal, undergoing Phase II development for the prevention of post-surgical staphylococcal infections, and XF-73 Dermal, which is in Phase I for treating bacterial skin infections resistant to antibiotics. Additionally, Destiny Pharma's preclinical efforts involve SPOR-COV, a biotherapeutic product aimed at preventing COVID-19 and other viral respiratory diseases, and XF Drugs Biofilm, targeting antibiotic-resistant biofilm and bacterial aggregate infections. The company is also investigating further applications of its XF drugs for respiratory, oral mucosa, and ocular infections. Destiny Pharma maintains strategic alliances with various organizations, including China Medical System Holdings Limited, SporeGen Limited, the University of Southampton, Aston University, the University of Sheffield, Cardiff University, and Tianjin Medical University.
Share Price
$0.04082105
Last synced: 2024-08-12
Market Cap
$39.09K
Change (1 day)
-19.83%
Change (1 year)
0.00%
Country
GB
Trade Destiny Pharma plc (DEST)

Category

Healthcare
Revenue for Destiny Pharma plc (DEST)
Revenue in Dec 2023 TTM: $1.06M
According to Destiny Pharma plc latest financial reports the company's current revenue (TTM) is $1.06M. In 2022 the company made a revenue of $186.91K an increase over the revenue in the year 2021 that was $182.56K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Destiny Pharma plc from 2013 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $1.06M 0.00%
2023 $1.06M 466.34%
2022 $186.91K 2.39%
2021 $182.56K 972.50%
2020 $17.02K -95.80%
2019 $405.66K 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 1,192,485.48%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 568,715.68%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 955,040.28%
BE